Sandoz Resolves Generic Drug Antitrust Investigation in the U.S.

Princeton, New Jersey, March 2, 2020 – Sandoz Inc. has reached a resolution with the U.S. Department of Justice (DOJ) Antitrust Division concerning the Department’s more than three-year-long antitrust investigation into the U.S. generic drug industry. The Sandoz resolution relates to instances of misconduct at the company between 2013 and 2015 with regard to certain generic drugs sold in the United States. As part of the resolution, Sandoz has agreed to pay USD 195 million and will enter into a deferred prosecution agreement (DPA).

Sandoz is a global leader in …

/by

Novartis provides update on use and safety of Beovu® in patients with wet AMD

March 11, 2020

Patient safety is at the heart of everything we do. Whenever adverse events are reported, we take them seriously and investigate them thoroughly. 

As previously shared, our global safety organization is conducting a comprehensive review of a limited number of events reported as severe vision loss, retinal artery occlusion and/or vasculitis in patients treated with Beovu, including cases where patients had previously received other VEGF inhibitors. 

To date, the data continue to support an overall favorable benefit-risk profile for …

/by

Sandoz Resolves Generic Drug Antitrust Investigation in the U.S.

Princeton, New Jersey, March 2, 2020 – Sandoz Inc. has reached a resolution with the U.S. Department of Justice (DOJ) Antitrust Division concerning the Department’s more than three-year-long antitrust investigation into the U.S. generic drug industry. The Sandoz resolution relates to instances of misconduct at the company between 2013 and 2015 with regard to certain generic drugs sold in the United States. As part of the resolution, Sandoz has agreed to pay USD 195 million and will enter into a deferred prosecution agreement (DPA).

Sandoz is a global leader in generic …

/by